🟢 Nuvation Bio is trading 4.1% up today after J.P. Morgan initiated coverage with an Overweight rating

Nuvation Bio is trading 4.1% up at $6.75 after J.P. Morgan initiated coverage on August 18, 2026, with an Overweight rating and a $13 December 2027 price target.

• The analyst cited IBTROZI’s early commercial launch trajectory and $23.2 million in second-quarter product sales.
• The bullish call is the clearest explanation for the advance, despite broader U.S. markets trading lower.
• Volume was 1.71 million shares versus a 5.95 million average daily volume, indicating below-average activity during the session.